Interim report Q1 2024
Business Highlights during the first quarter 2024
- Announcing the achievement of the first milestone under the agreement with Curium Inc. to develop uTRACE® for improving diagnosis of prostate cancer.
- The Company remains committed to accelerating its therapeutic strategy and is currently evaluating alternative financing options.
- After the end of Q1 the Company received acceptance of the clinical trial application from the European Medicines Agency for the investigation of uTRACE® in a phase 2 trial.
Copenhagen, Denmark, 23 May 2024 - Curasight A/S (“Curasight” or “the Company” – TICKER: CURAS) hereby publishes the Interim report Q1 2024. The interim report is available as an attached file to this release and on the Company’s website. Below is a summary of the report.
“We had another busy quarter as we have continued to build on our successes from the past year. In particularly we were pleased to receive the first milestone payment from Curium under our agreement for uTRACE® in prostate cancer. This shows the progress in the uTRACE® product as the milestone relates to validation of GMP manufacturing of the finished product.”, stated Curasight’s CEO Ulrich Krasilnikoff. We also updated our clinical strategy to accelerate development of our therapeutic platform uTREAT® and ensure parallel development with our uTRACE® diagnosis platform. Finally, due to the challenging climate at the capital market we decided to withdraw a planned right issue in Q1 with the purpose to pursue other options. We look forward to being able to announce progress in these alternative funding options soon.”
Q1 (2024-01-01 – 2024-03-31)
- Gross loss amounted to kDKK -7,385 (kDKK -4,656)
- Operating loss amounted to kDKK -9,376 (kDKK -6,184)
- Loss before tax amounted to kDKK -9,367 (kDKK -6,186)
- Loss for the period amounted to kDKK -7,992 (kDKK -4,826)
- Total assets amounted to kDKK 27,574 (kDKK 54,745)
- Equity ratio amounted to 84,8% (96,3%)
- Earnings per share amounted to DKK -0,40 (DKK -0,24)
